# Zymergen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zymergen

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.zymergen.com
- Total disclosed funding: $882M
- Latest round: Series D (Sep 8, 2020)
- Investors on record: 18

## About

Zymergen, Inc., based in the US, operates as a biotechnology company focused on harnessing the power of biology and technology to develop innovative materials and products for diverse industries.Zymergen, Inc. specializes in biotechnology, creating advanced materials and products through innovative biological processes. Founded in 2013 in Emeryville, US, the company has undergone significant changes, culminating in an IPO on April 21, 2021, raising USD 500.03 mn. The firm was co-founded by Josh Hoffman and Zach Serber, with Jay Flatley serving as CEO. Zymergen has raised a total of USD 500.03 mn across multiple funding rounds, and its most recent funding was an IPO. In July 2022, Zymergen was acquired by Ginkgo BioWorks, Inc. for an undisclosed amount, enhancing Ginkgo's platform capabilities.Zymergen, Inc. provides a range of biotechnology solutions aimed at various sectors, including agriculture and biopharma. The company develops innovative materials and products utilizing genetic engineering and advanced biological processes. Key offerings include AI-driven models for optimizing production, lab automation systems, and customized R&D services tailored to the specific needs of clients in the agricultural and pharmaceutical industries. Zymergen actively collaborates with firms and government agencies in North America, Europe, and parts of Asia, supporting their innovation and product development efforts.In 2021, Zymergen, Inc. reported a revenue of USD 16.74 mn. Despite this revenue, the company experienced a significant EBITDA loss of USD 326.87 mn during the same year, reflecting the challenges and costs associated with its innovative biotech operations.Following its IPO on April 21, 2021, Zymergen, Inc. plans to utilize the raised USD 500.03 mn to accelerate the production of its Hyaline film and expedite the commercialization of other products. The company aims to expand its operations into new markets, specifically targeting regions in Asia and Europe by the end of 2023. The acquisition by Ginkgo BioWorks, completed in October 2022, is expected to further enhance Zymergen's capabilities and market reach, supporting its strategic initiatives to develop new biotechnology solutions.

## Funding rounds

- Series D, Sep 8, 2020, $300M — True Ventures, DCVC, Baron Capital, Perceptive Advisors, SB Investment Advisers, Baillie Gifford
- Series C, Nov 30, 2018, $407M — Draper Fisher Jurvetson, True Ventures, Two Sigma Investments, Goldman Sachs Asset Management, Innovation Endeavors, DCVC, SB Investment Advisers, Hanwha Asset Management
- Series B, Oct 7, 2016, $130M — Draper Fisher Jurvetson, True Ventures, Two Sigma Investments, SoftBank Group, Innovation Endeavors, DCVC, ICONIQ Capital, AME Cloud Ventures, Prelude Ventures, Obvious, Tao Capital Partners
- Series A, Jun 5, 2015, $44M — Draper Fisher Jurvetson, True Ventures, HVF, Two Sigma Investments, Innovation Endeavors, DCVC, AME Cloud Ventures, Obvious
- Seed, Jun 1, 2013, $2M — DCVC

## Investors

- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A, Series B, Series C, Series D
- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series A, Series B, Series C
- True Ventures (https://capitalatlas.ai/funds/true-ventures) — Series A, Series B, Series C, Series D
- HVF — Series A
- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Series A, Series B, Series C
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series A, Series B, Series C
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Series A, Series B
- Obvious (https://capitalatlas.ai/funds/obvious) — Series A, Series B
- SoftBank Group — Series B
- ICONIQ Capital (https://capitalatlas.ai/funds/iconiq-capital) — Series B
- Prelude Ventures — Series B
- Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C, Series D
- Hanwha Asset Management (https://capitalatlas.ai/funds/hanwha-asset-management) — Series C
- Baron Capital — Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series D
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series D